Genprex Inc (GNPX) Stock Price, Quote & News

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 774 4679

Website: www.genprex.com

Address:

3300 Bee Cave Road, Suite 650-227, Austin, United States

MB76 Feb. 26 at 2:38 PM

$GNPX Did you see this? See you at $.49?

1 · Reply

BennyBenneth Feb. 26 at 2:35 PM

$GNPX Good thing I could scoop a little under 2 this morning.

1 · Reply

MB76 Feb. 26 at 2:29 PM

$GNPX I’m generally concerned

0 · Reply

MB76 Feb. 26 at 2:28 PM

$GNPX Have they announced another dilution yet?

0 · Reply

StockCaptain7 Feb. 26 at 9:18 AM

$GNPX Simple math. Chronic Care = Expensive (Drain on Budget) Gene Therapy = Cure (Saves Billions) Rep. Tim Moore is effectively hedging the US Healthcare budget. If GNPX works, it is not just a 100x stock, it is a massive cost-saver for the government. He is not buying the chart. He is buying the solution.

0 · Reply

StockCaptain7 Feb. 26 at 9:17 AM

$GNPX Don't Forget Where He's From People think Tim Moore is just guessing on GNPX. They forget he spent a decade leading North Carolina, which is a top 3 global biotech hub. He knows the regulatory binary and FDA phases better than 99% of Congress because his home state's economy is built on it. When a politician from a biotech stronghold starts loading a specific micro-cap 3 times in 5 months, it is not a gamble. It is an educated bet on the home team's sector.

0 · Reply

StockCaptain7 Feb. 26 at 9:16 AM

$GNPX Everyone is asking why Tim Moore is buying a micro-cap gene therapy stock like GNPX. Tim Moore is a fiscal hawk. His job is to cut government spending. Chronic diseases like Diabetes are the number one drain on Medicare and Medicaid. They cost the US billions every year in lifetime care. Gene Therapy is a one and done cure. It eliminates the lifetime cost. He isn't just betting on science. He is betting on the only deflationary technology that can actually save the federal budget. Cures are cheaper than care. That is the Budget Committee play.

0 · Reply

StockCaptain7 Feb. 26 at 8:44 AM

$GNPX https://www.webullapp.co.uk/news-detail/14441155192349696?theme=1&hl=en&color=2&_v=1&tickerId=950052394&disSymbol=GNPX&sourcePage=Stock_NewsList&sp=0&hl=en

0 · Reply

ACInvestorBlog Feb. 25 at 8:55 PM

$GNPX Volume is drying up.... Pullback over imho... MACD is curling up....

1 · Reply

_Moony4x Feb. 25 at 7:50 PM

$GURE $CYCU $QTI $GNPX 3

0 · Reply

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Feb 10, 2026, 8:00 AM EST - 16 days ago

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Jan 7, 2026, 7:00 AM EST - 7 weeks ago

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Jan 6, 2026, 7:00 AM EST - 7 weeks ago

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Nov 24, 2025, 7:00 AM EST - 3 months ago

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Nov 19, 2025, 7:00 AM EST - 3 months ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Nov 18, 2025, 7:00 AM EST - 3 months ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Nov 4, 2025, 7:00 AM EST - 4 months ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Oct 28, 2025, 11:19 AM EDT - 4 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 7:00 AM EDT - 4 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 8:12 AM EDT - 4 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 7:00 AM EDT - 4 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 2, 2025, 8:30 AM EDT - 6 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Aug 18, 2025, 9:29 AM EDT - 6 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 4, 2025, 8:30 AM EDT - 7 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Jun 24, 2025, 9:25 AM EDT - 8 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 8 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 3, 2025, 7:00 AM EDT - 9 months ago

Genprex to Participate at BIO 2025 International Convention

May 29, 2025, 7:00 AM EDT - 9 months ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 28, 2025, 7:00 AM EDT - 9 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 7, 2025, 7:00 AM EDT - 10 months ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 6, 2025, 7:00 AM EDT - 10 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Apr 30, 2025, 7:30 AM EDT - 10 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 10 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 28, 2025, 7:30 AM EDT - 10 months ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 24, 2025, 8:15 AM EDT - 11 months ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 22, 2025, 8:15 AM EDT - 11 months ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 25, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 4, 2025, 8:15 AM EST - 1 year ago

Genprex to Participate at BIO Europe Spring 2025

Feb 19, 2025, 8:15 AM EST - 1 year ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 18, 2025, 8:15 AM EST - 1 year ago

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 13, 2025, 8:15 AM EST - 1 year ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 7, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Sep 23, 2024, 9:29 AM EDT - 1 year ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Sep 19, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Sep 4, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Aug 15, 2024, 9:30 AM EDT - 1 year ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Aug 14, 2024, 9:25 AM EDT - 1 year ago

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Aug 13, 2024, 8:31 AM EDT - 1 year ago

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

MB76 Feb. 26 at 2:38 PM

$GNPX Did you see this? See you at $.49?

1 · Reply

BennyBenneth Feb. 26 at 2:35 PM

$GNPX Good thing I could scoop a little under 2 this morning.

1 · Reply

MB76 Feb. 26 at 2:29 PM

$GNPX I’m generally concerned

0 · Reply

MB76 Feb. 26 at 2:28 PM

$GNPX Have they announced another dilution yet?

0 · Reply

StockCaptain7 Feb. 26 at 9:18 AM

0 · Reply

StockCaptain7 Feb. 26 at 9:17 AM

0 · Reply

StockCaptain7 Feb. 26 at 9:16 AM

0 · Reply

StockCaptain7 Feb. 26 at 8:44 AM

$GNPX https://www.webullapp.co.uk/news-detail/14441155192349696?theme=1&hl=en&color=2&_v=1&tickerId=950052394&disSymbol=GNPX&sourcePage=Stock_NewsList&sp=0&hl=en

0 · Reply

ACInvestorBlog Feb. 25 at 8:55 PM

$GNPX Volume is drying up.... Pullback over imho... MACD is curling up....

1 · Reply

_Moony4x Feb. 25 at 7:50 PM

$GURE $CYCU $QTI $GNPX 3

0 · Reply

MB76 Feb. 25 at 7:29 PM

$GNPX This is the DUMP before the DUMP!!!!!!!!

0 · Reply

_Moony4x Feb. 25 at 7:19 PM

$PARR $HOLO $GNPX $ABAT @@@

0 · Reply

ACInvestorBlog Feb. 25 at 6:34 PM

$GNPX I think investors are not aware how powerful Monday news was…. This was a significant positive catalyst for a micro-cap biotech like Genprex, as stronger global IP can de-risk the program, attract partners, or support future funding/valuation. These patents (with Genprex holding exclusive licenses) expand protection in major markets (Japan and Europe), building on prior U.S. and other approvals 👌

0 · Reply

POSGNPX Feb. 25 at 6:19 PM

$GNPX

0 · Reply

MB76 Feb. 25 at 4:51 PM

$GNPX This stock and the company behind it is dead!!

0 · Reply

MB76 Feb. 25 at 4:49 PM

$GNPX When is the next dilution?

0 · Reply

ACInvestorBlog Feb. 25 at 4:33 PM

$GNPX impressive money flow in the last two sessions.

0 · Reply

Disrupter Feb. 25 at 4:20 PM

$GNPX * float 2.2M * FTD’ed pipeline * data in early 2026 * short float = 22%⛽️

0 · Reply

StockCaptain7 Feb. 25 at 3:54 PM

$GNPX I still can’t get my head around this one… a sitting Congressman filing a buy in a $5M microcap? 🤯 That’s not your normal “safe” DC portfolio move. Maybe it’s nothing and it’s just a tiny punt… but if you’re that high up, why even bother clicking buy unless you’ve seen something you actually like? Could be I’m reading too much into it. Could be he knows something. Either way… time will tell. 👀 #biotech #microcap #congressTrades

1 · Reply

greanbeen Feb. 25 at 3:38 PM

$XWEL $GNPX runners today

0 · Reply

greanbeen Feb. 25 at 3:32 PM

$GNPX let’s run it back up!!!

0 · Reply

greanbeen Feb. 25 at 3:14 PM

$GNPX needs volume

0 · Reply

Market Cap	6.94M
Revenue (ttm)	0.00
Net Income (ttm)	-21.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,502,300
Avg Vol	1,135,930
Day's Range	N/A - N/A
Shares Out	3.12M
Stochastic %K	30%
Beta	-0.78
Analysts	Strong Buy
Price Target	$7.50